ESR1 and breast carcinoma: While tremendous advances have been made in other subtypes of breast cancer such as HER2+ tumors with the development of targeted agents against the HER2 receptor and ER+ breast cancers with agents to block estrogen signaling, there are no approved targeted treatments for TNBC.